Latres, Esther
Mastaitis, Jason http://orcid.org/0000-0002-9991-3509
Fury, Wen
Miloscio, Lawrence
Trejos, Jesus
Pangilinan, Jeffrey
Okamoto, Haruka
Cavino, Katie
Na, Erqian
Papatheodorou, Angelos
Willer, Tobias
Bai, Yu
Hae Kim, Jee
Rafique, Ashique
Jaspers, Stephen
Stitt, Trevor http://orcid.org/0000-0002-2614-0277
Murphy, Andrew J.
Yancopoulos, George D.
Gromada, Jesper
Article History
Received: 8 September 2016
Accepted: 6 March 2017
First Online: 28 April 2017
Competing interests
: All authors except E.L. and T.W. are current employees of Regeneron Pharmaceuticals. E.L. and T.W. were employees of Regeneron Pharmaceuticals when this study was conducted. J.M., W.F., L.M., J.T., J.P., H.O., K.C., E.N., A.P., Y.B., J.H.K., A.R., S.J., T.S., A.J.M., G.D.Y. and J.G. are currently employees and hold stock or stock options of Regeneron Pharmaceuticals. Regeneron Pharmaceuticals and E.L., T.S., A.J.M., G.D.Y. and J.G. hold patents for antibodies inhibiting GDF8 and activin A and uses thereof.